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Abstract
Background
We investigated the correlation between pancreatic ductal adenocarcinoma patient progno-
sis and the presence of tumour infiltrating lymphocytes and expression of 521 immune sys-
tem genes.
Methods
Intratumoural CD3+, CD8+, and CD20+ lymphocytes were examined by immunohistochem-
istry in 12 PDAC patients with different outcomes who underwent pancreaticoduodenect-
omy. The results were correlated with gene expression profile using the digital multiplexed
NanoString nCounter analysis system (NanoString Technologies, Seattle, WA, USA).
Results
Twenty immune system genes were significantly differentially expressed in patients with a
good prognosis relative to patients with a worse prognosis: TLR2 and TLR7 (Toll-like recep-
tor superfamily); CD4, CD37, FOXP3, PTPRC (B cell and T cell signalling); IRF5, IRF8,
STAT1, TFE3 (transcription factors); ANP32B, CCND3 (cell cycle); BTK (B cell develop-
ment); TNF, TNFRF1A (TNF superfamily); HCK (leukocyte function); C1QA (complement
system); BAX, PNMA1 (apoptosis); IKBKE (NFκB pathway). Differential expression was
more than twice log 2 for TLR7, TNF, C1QA, FOXP3, and CD37.
Discussion
Tumour infiltrating lymphocytes were present at higher levels in samples from patients with
better prognosis. Our findings indicate that tumour infiltrating lymphocyte levels and expres-
sion level of the immune system genes listed above influence pancreatic ductal
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adenocarcinoma prognosis. This information could be used to improve selection of best
responders to immune inhibitors.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease often with a poor prognosis [1].
PDAC is characterized by a desmoplastic, highly heterogeneous and immune-suppressive
microenvironment that hinders antitumour immunity. PDACs tend to recruit immunosup-
pressive cells including myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs)
and tumour-associated macrophages (TAMs). PDACs also inhibit immune effector cells,
mainly CD4+ CD8+ T lymphocytes, natural killer (NK) cells and dendritic cells (DCs) [2].
Some PDACs, moreover, overexpress programmed death ligand 1 (PDL1) and secrete inhibi-
tory cytokines such as interleukin 10 (IL10) and tumour growth factor β (TGFβ) [3]. Desmo-
plasia, another hallmark of PDAC, is characterized by a noticeable proliferation of
myofibroblasts and generates a strong barrier against tumour infiltration by both immune
cells and drugs [4].
The correlation between tumour infiltrating lymphocytes (TILs) and clinical outcomes has
been investigated in several studies involving PDAC patients. Fukunaga et al found that
patients with CD8+ tumours had a higher five-year overall survival (OS) rate than patients
with CD8- tumours, and similarly for patients with CD4+ tumours versus CD4- tumours [5].
Evaluating the prognostic value of CD3+, CD8+, and CD20+ TILs, Tewary et al found an asso-
ciation between CD3+ and CD20+ TILs and a higher survival rate [6]. Furthermore, Ino et al
found that patients with high CD8+ and CD4+ TIL and low Treg counts had a better survival
rate than patients with low CD8+ and CD4+ TIL and high Treg counts [7]. Patients with CD4+
tumours were found to have OS and disease-free survival (DFS) higher than patients with
CD4- tumours, and a high CD8+/FoxP3+ lymphocyte ratio correlated with better clinical out-
comes, but no significant correlation was found between CD8+ TILs and survival or other clin-
ical-pathological features [8]. Karakhanova et al found that CD4+ and CD8+ count correlated
with higher OS and DFS [9].
The immune system interacts intimately with tumours over the entire process of disease
development. This complex immune system-tumour cross-talk can both inhibit and enhance
tumour growth [10]. Major features of the process by which tumours escape the immune sys-
tem include a reduction in the recognition of cancer antigens by immune cells and the devel-
opment of an immune suppressive microenvironment. The tumour microenvironment of
PDAC has been consistently reported to be capable of promoting immune escape, rendering
the immune system ineffective in eliciting an anti-tumour response. Improved understanding
of the tumour microenvironment and how it contributes to immune evasion could, therefore,
lead to better treatments and outcomes for PDAC patients [11]. This motivated our investiga-
tion of differences in TILs and immune-related gene expression between PDAC patients with
good and worse clinical outcomes.
Materials & methods
Patients and sample collection
Fresh PDAC specimens were obtained from patients (n = 12) undergoing surgical resection at
the Department of Medical, Surgical & Health Sciences, Cattinara Teaching Hospital, Trieste
University, between 2005 and 2015. These experiments were approved by Trieste University
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Institutional Review Board. Tissue specimens were snap frozen in liquid nitrogen and stored
at −80˚C.
Formalin-fixed, paraffin wax-embedded sections were used for immunohistochemical
staining. All 12 paraffin wax blocks were confirmed to contain tumour tissue by two patholo-
gists, comprising six pancreatic adenocarcinomas with a good prognosis and six pancreatic
adenocarcinomas with a bad prognosis.
The following clinical data were collected: patient age, gender, and outcome; the presence/
absence of metastasis; tumour location, size, margin status, TNM stage, degree of differentia-
tion, invasion degree and location (lymph node, bile duct/duodenal serosa, hepatic, portal
vein, vascular, perineural), schedule of chemotherapy, neoadjuvant and/or adjuvant chemo-
therapy, chemotherapy toxicity, and treatment follow up. Clinical Stadiation of patients ranged
from stage IA to III but none of them was metastatic and none of them underwent chemother-
apy. Patients were informed about the project and gave written consent for study participation.
Of note, a caveat to the study is that sample was relatively scarce because of the intrinsically
hard-to-reach nature of the disease plus the requirement to put aside part of every sample for
storage at the institution as per legal and ethical regulations.
Follow up
OS was measured from the time of surgery to the time of death or the last follow up visit. Dates
of death were obtained from patient hospital records or follow up telephone calls. A more in-
depth analysis of the 12 patients revealed two groups with different DFS and/or OS: six patients
with an OS between 25 and 66 months were classified as “good cases”, while six with OS
between 2 and 9 months or DFS between 1 and 2 months were classified as “worse cases”.
Table 1 summarizes the clinical-pathological data of the two groups of patients and Fig 1
shows the Kaplan-Meier curves for DFS and OS for the two groups of patients.
PanCancer immune profile panel multiplex gene expression profiling
Three patients were randomly selected from each of the good and worse prognosis groups. In
accord with Koti et al [12], pathologists in our department selected and extracted two areas of
at least 70% of cellularity from each formalin-fixed, paraffin wax-embedded tumour tissues,
and total RNA was extracted using Qiagen RNeasy (Qiagen Inc., Toronto, ON, Canada) as per
the manufacturer’s instructions. A NanoDrop ND-100 spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE, USA) was used to measure RNA concentration and purity. All
RNA samples included in the study passed the quality control requirements (as verified by
RNA integrity number or OD 260/280 ratio) of the platform. Using 100 ng total RNA from
each sample as input, according to the manufacturer’s instructions, the digital multiplexed
NanoString nCounter analysis system (NanoString Technologies, Seattle, WA, USA) was used
for gene expression profiling. Tumour RNA samples were analysed using nCounter PanCan-
cer immune profile panel consisting of 770 human immune-related genes (Nanostring
Technologies).
In this assay, colour-coded barcodes are used to represent single-target transcripts in the
reaction. An overnight hybridisation reaction was used to incorporate the resulting material,
carried out by combining 20 ml of nCounter Reporter probes in hybridisation buffer, 5 ml of
nCounter Capture probes and 5 ml of the total RNA sample for a total reaction volume of 30
ml. The hybridisations were incubated at 65˚C for 16–20 h. An excess of probes is provided
during overnight hybridization to ensure that each target finds a probe pair. Target abundance
values can then be determined through the nCounter Digital Analyzer by counting the indi-
vidual fluorescent barcodes. A high-density scan was performed for each assay (encompassing
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600 fields of view). After hybridisation, the cartridges were analysed in the Digital Analyzer
that counts (representing the number of molecules) and arranges the barcodes.
Immunohistochemistry
An automatic stainer (BenchMark ULTRA, Ventana Medical System, Inc.) was used for the
immunohistochemical test. The antigen was retrieved with cell conditioning buffer 1. Next,
endogenous peroxidase was inhibited with H2O2 at 3% (Bioptica) for 10 min. Samples were
incubated with primary antibody anti-CD3 (2GV6) (Roche-Ventana), anti-CD8 (SP57)
(Roche-Ventana), Rabbit Monoclonal Pre-diluted (0.4μg/mL), for 20 min at 36˚C; anti-CD20
(L26) (Roche-Ventana), Mouse Monoclonal Pre-Diluted (0.4μg/mL) for 24 min at 36˚C. The
antibody was exposed with ultraView Universal DAB Detection Kit (Cat No. 760–500). As
counterstain, Mayer haematoxylin was used for 4 min.
TIL levels were assessed by two investigators blind to the patients’ clinical-pathological data
using the standardized method coded in 2015 by the International TILs Working Group [13].
TILs were investigated per microscopic field (5X and 10X) and an average over ten indepen-
dent regions having the most abundant immunoreactive cells was calculated for each slide.
Immunohistochemistry statistical analysis
For immunohistochemistry statistical analysis, a preliminary data exploration was performed.
Numerical variables were expressed as median and range and were compared by non-
parametric tests (Mann–Whitney U-test). Qualitative data were expressed as frequencies and
Table 1. Summary of patient clinical-pathological information. ECOG: Eastern Cooperative Oncology Group (Per-
formance Status); TNM Stadiation: T = Tumour (0–4), N = Nodes (0–2), M = Metastasized (0–1).
Good cases Worse cases
Num. Pts 6 6
Age 65.3 63.8
Gender
Male 4 3
Female 2 3
ECOG
0 2 0
1 2 3
2 1 2
Not reported 1 1
TNM
T
T0 0 0
T1 1 2
T2 0 4
T3 4 0
T4 1 0
N
N0 2 2
N1 4 4
M
M0 6 6
STAGE IA/IIA/IIB/III IB/IIA/IIB
https://doi.org/10.1371/journal.pone.0219566.t001
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organized into contingency tables; the association between categorical variables was investi-
gated by means of Fisher’s exact test or Pearson’s Chi-square. Time-dependent variables were
calculated according to the Kaplan–Meier method. For the entire statistical analysis, the signif-
icance levels were established at p<0.05. All data were analysed with STATA software.
Immune profile panel multiplex nanoString statistical analyses
NanoString data analysis. nSolver (NanoString Technologies) was used for the normali-
zation of raw data as previously reported [14]. The raw NanoString counts were initially sub-
jected to normalization for all target RNAs in all samples based on built-in positive controls.
This step accounts for post-hybridization processing, inter-sample and experimental variation
such as hybridization efficiency. The geometric mean of each of the controls was calculated,
indicating the overall assay efficiency. For the mRNA content normalisation, housekeeping
genes were then used. To facilitate downstream statistical analysis, values < 0 were blanketed
and considered equal to 1. After initial normalisation steps, data were imported to GraphPad
Prism (GraphPad Software, Inc., La Jolla, CA, USA) to be processed for statistical analysis.
Multiple t-tests were performed with correction for multiple comparisons through the Sidak–
Bonferroni method. A difference in expression with a P-value of� 0.05 was considered statis-
tically significant.
Results
Immune-related gene expression analysis in pancreatic adenocarcinomas
with good versus worse prognosis
Prognosis of primary PDAC patients was determined using clinical data and Kaplan-Meier
curves (Fig 1). Three primary PDAC patients with a good prognosis and three with a worse
prognosis were then chosen for mRNA analysis by PanCancer Immune Profile Panel multiplex
gene expression analysis. Fig 2 shows the differential gene expression. Among the immune sys-
tem genes showing statistically significant (p<0.01) differential expression between pancreatic
adenocarcinoma with a good and worse prognosis, differential expression of TLR7, TNF,
C1QA, FOXP3, and CD37 was at least twice log 2: +2.76 log 2 ± 0.58 (p<0.00896), +2.39 log
2 ± 0.389 (p<0.00356), +2.19 log 2 ± 0.43 (p<0.00697), +2.07 log 2 ± 0.372 (p<0.00513), and
+2 log 2 ± 0.297 (p<0.00254), respectively (S1 Fig). BTK (+1.91 log 2 ± 0.309 (p<0.0035)),
CD4 (+1.86 log 2 ± 0.235 (p<0.00138)), HCK (+1.86 log 2 ± 0.304 (p<0.00364)), PTPRC
(+1.83 log 2 ± 0.259 (p<0.00211)), CCND3 (+1.67 log 2 ± 0.337 (p<0.00777)), STAT1 (+1.59
log 2 ± 0.238 (p<0.00626)), IKBKE (+1.51 log 2 ± 0.282 (p< 0.00585)), IRF8 (+1.43 log
2 ± 0.246 (p<0.00439)), TNFRF1A (+1.39 log 2 ± 0.298 (p<0.00954)), TLR2 (+1.34 log
2 ± 0.147 (p<0.000799)), BAX (+1.31 log 2 ± 0.246 (p<0.00598)), IRF5 (+1.27 log 2 ± 0.193
(p<0.00272)), PNMA1 (+0.986 log 2 ± 0.201 (p<0.00799)), ANP32B (+0.92 log 2 ± 0.163
(p<0.00484)), TFE3 (-0.37 log 2 ± 0.0783 (p<0.00919)), and mRNA also showed statistically
significant (p<0.01), but less than twice log 2, differential expression between pancreatic ade-
nocarcinomas with good and worse prognosis (Table 2).
Gene expression analysis indicated that the pancreatic adenocarcinoma group with a good
prognosis showed higher levels of the following cell types compared to the group with a worse
prognosis (Figs 3–5): CD45-expressing cells, Tregs, DCs, macrophages, NK CD56dim cells, T
cells, exhausted CD8+ cells, cytotoxic cells, mast cells, CD8+ T cells and neutrophils (Figs 3 and
4). Box plot representations indicate that the following subtypes of cells exhibit particularly dif-
ferent levels: CD45-expressing cells, dendritic cells, macrophages, natural killer cells, the family
of T cells (Fig 5), and exhausted CD8+ and Treg cells (S1–S3 Figs).
Immune genes and cells in pancreatic cancer
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Tumour immune cell profiling in pancreatic adenocarcinomas with good
versus worse prognosis
In agreement with existing data [5–9], tumour immune cell marker levels were higher in good
prognosis cases compared to worse prognosis cases (Table 3). The CD3 level was statistically
higher in the good prognosis group compared to the worse prognosis group (p = 0.0267,
Table 4), (Fig 6). Despite the fact that the number of CD8+ and CD20+ cells has been found to
be higher in patients with good prognosis in our study, no statistically significant difference
was found between the two subgroups of immune cells (p = 0.119 and p = 0.925, respectively)
(Table 4), (Fig 6). TIL marker levels were not assessed in one case due to calcification in pan-
creatic ductal tissue. Fig 7 shows the detection of TILs in the two sets of six PDAC patients.
Staining for TILs was visually negative in the adenocarcinomas with a worse prognosis while it
was positive for the adenocarcinomas with a good prognosis.
Fig 1. Worse and good prognosis PDAC patient groups. Kaplan-Meier curves show the difference of OS or DFS
between two groups of patients: one group with a worse prognosis (“worse”, blue line) and the other with a better
prognosis (“good”, red line).
https://doi.org/10.1371/journal.pone.0219566.g001
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Discussion
Immune cells within the cancer infiltrate may have a role in fighting cancer growth via antigen
restricted tumouricidal responses or they may promote tumour progression by suppressing
the immune system [15]. There are three major barriers impeding immune therapy in PDAC:
1. The mutational load in PDAC is much lower than that of lung cancers and melanoma; 2.
PDAC has a strong immunosuppressive microenvironment which is composed of a dense des-
moplastic reaction having remarkable infiltration of tumourigenic MDSCs and macrophages
[16]; 3. The PDAC microenvironment has a very low number of infiltrating T cells, insufficient
to provide a significant T cell response.
In the current study, PDAC samples from patients with a good prognosis had higher levels
of TILs compared to a group of patients with a worse prognosis, as assessed via immune
marker levels. Even though the patient numbers are small and the selection of good prognosis
or worse prognosis somewhat arbitrary (based on clinical data and Kaplan-Meier curves) (Fig
1), the correlation is consistent with previous reports suggesting that TIL levels provide a
robust predictor of outcome in pancreatic cancer [8,17]. Consistent with data reported by
Stromness et al, we point out that in some samples of the “Good” prognosis group, CD3+ cells
tend to organise in tertiary lymphoid structures (TLS) within tumour stroma [18]. Although
there is limited knowledge of TLS, these formations are commonly found in solid tumour with
a better prognosis, suggesting their possible role in T cell regulation of in-situ immune
response[18]. Furthermore, our study revealed a significant (p-value<0.001) differential
Fig 2. Differential gene expression between “good prognosis cases” and “worse prognosis cases” of PDAC.
Volcano plot in which the larger red dots represent only those genes whose expression is at least twice log2 higher in
“good cases” (Group B) relative to “worse cases” (Group A) with p-value< 0.01. Genes with highly statistically
significant differential expression fall at the top of the plot above the horizontal lines, and highly differentially
expressed genes fall to either side depending on whether they are negatively or positively differentially expressed.
Horizontal lines indicate various False Discovery Rate (FDR) thresholds or p-value thresholds if there is no adjustment
to the p-values. Genes are red if the resulting p-value is below the given FDR or p-value threshold. The 20 genes
showing the most statistically significant differential expression are labelled in the plot.
https://doi.org/10.1371/journal.pone.0219566.g002
Immune genes and cells in pancreatic cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0219566 August 5, 2019 7 / 19
expression of 20 immune system genes between PDAC patients with good and worse progno-
ses. Among these genes, the expression of five (TLR7, TNF, C1QA, FOXP3, CD37) was at least
twice log 2 higher in the good prognosis group relative to the worse prognosis group. Expres-
sion levels of these five genes could constitute a molecular signature of likely outcome and
could therefore be useful for clinical applications.
Table 2. Top 20 genes differentially expressed between “good cases” and “worse cases”.
Genes Differential expression between “good cases” and “worse cases” (log2 fold change) Std error P-Value
TLR7-mRNA 2.76 0.58 0.00896
TNF-mRNA 2.39 0.389 0.00356
C1QA-mRNA 2.19 0.43 0.00697
FOXP3-mRNA 2.07 0.372 0.00513
CD37-mRNA 2 0.297 0.00254
BTK-mRNA 1.91 0.309 0.0035
CD4-mRNA 1.86 0.235 0.00138
HCK-mRNA 1.86 0.304 0.00364
PTPRC-mRNA 1.83 0.259 0.00211
CCND3-mRNA 1.67 0.337 0.00777
STAT1-mRNA 1.59 0.238 0.00262
IKBKE-mRNA 1.51 0.282 0.00585
IRF8-mRNA 1.43 0.246 0.00439
TNFRSF1A-mRNA 1.39 0.298 0.00954
TLR2-mRNA 1.34 0.147 0.000799
BAX-mRNA 1.31 0.246 0.00598
IRF5-mRNA 1.27 0.193 0.00272
PNMA1-mRNA 0.986 0.201 0.00799
ANP32B-mRNA 0.92 0.163 0.00484
TFE3-mRNA -0.37 0.0783 0.00919
https://doi.org/10.1371/journal.pone.0219566.t002
Fig 3. Tumour immune cell profiling by immunohistochemical analysis. Trend plot summarizing the change in abundance of cell types from “worse cases” (A) to
“good cases” (B).
https://doi.org/10.1371/journal.pone.0219566.g003
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FOXP3 is a well known marker of Tregs, with a pivotal role in the development and differ-
entiation of these cells to promote tumour immune escape [19,20]. Conversely, FOXP3 has
been reported to be an important tumour suppressor gene in breast cancer [21–25], gastric
Fig 4. Heat map showing the levels of the different cell types in “worse cases” (pink) and “good cases” (grey). Yellow-orange indicates high abundance, blue
indicates low abundance.
https://doi.org/10.1371/journal.pone.0219566.g004
Immune genes and cells in pancreatic cancer
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adenocarcinoma [26,27], prostate cancer [28], and non-small cell lung cancer [29]. These find-
ings indicate that the roles of FOXP3 in tumours are diverse and situation-dependent.
C1QA encodes the A-chain polypeptide of complement subcomponent C1q and plays an
important role in counteracting tumour cells [30,31]. Teschendorff and Caldas et al showed
that overexpression of C1QA in ER-negative basal-like breast cancer patients is associated with
better prognosis [32]. It was shown more recently that lower C1QA expression could be linked
with worse outcomes in patients with ER-negative breast cancer [33]. Nonetheless, Bulla et al
Fig 5. Box plots. Box plots of measurements of CD45-expressing cells, dendritic cells, macrophages, NK, and T cells, in “good
cases” (B) and “worse cases” (A).
https://doi.org/10.1371/journal.pone.0219566.g005
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recently showed that C1q can exert functions unrelated to complement activation, contribut-
ing to extracellular changes within the tumour microenvironment and supporting tumour
growth and invasion [34]. This last finding is supported by Winslow et al [35].
TNF has long been considered a key regulator of the inflammatory and immune response
to cancer, promoting either death or survival under different circumstances [36]. Although
several anti-TNF therapies have been developed with different binding and pharmacokinetic
profiles [37], TNF is used in current therapies to fight cancer, notwithstanding its toxicity [38].
TNF has proved to have an effect on metastatic melanoma treatment and unresectable soft tis-
sue therapies [39,40]. There is evidence of TNF’s role in promoting regression of unresectable
hepatic metastasis from colorectal cancer [41] and in causing tumour necrosis via its pro-coag-
ulant effect [42].
TLR7 is of special interest in cancer therapy on account of its strong stimulation of IL-12
and type-I interferons, which are important cytokines and effectors of T and NK cell functions
[43,44]. TLR7 ligands can not only activate directly NK cells and cytotoxic T-cells [45,46], but
also hamper the suppressive function of myeloid-derived suppressor cells [47,48] and interfere
with the migration of Tregs into the tumour [49]. TLR agonists are clinically approved or
under clinical evaluation for cancer immunotherapy [50–52].
CD37 belongs to the tetraspanin superfamily of transmembrane proteins that regulate pro-
tein adhesion, trafficking, and migration and that are emerging controllers of both humoral
and immune control, especially stimulating dendritic cell migration and B cell survival [53–
55]. The contribution of CD37 to antitumour immunity has been known since the finding that
Table 3. Levels of CD3, CD8 and CD20 TIL subpopulations. Data are reported as a percentage value of stroma TILs
and are related to the sub-group assessed (CD3, CD8, CD20). For every antigen, two columns of values are reported,
each corresponding to a different pathologist’s evaluation. The final score has been given in a semi-quantitative way by
evaluating cell density in 10 digital images (20x enlargement) and calculating the average of all scores. The scores have
been given following the guidelines of the “International TILs Working Group 2014”.
Sample number CD3 CD8 CD20
Worse cases 1 6 7 5 9 1 2
2 Not performed
3 13 11 10 6 2 3
4 9 8 13 13 1 2
5 9 4 3 4 2 3
6 9 5 1 3 0 0
Good cases 1 10 8 10 9 2 3
2 10 8 5 3 0 1
3 23 16 6 12 0 0
4 10 8 10 8 0 1
5 27 16 15 13 5 4
6 16 15 15 11 2 3
https://doi.org/10.1371/journal.pone.0219566.t003
Table 4. Statistical difference of TIL levels between the two groups. The table summarizes the statistical difference
of TIL levels between the “worse case” and “good case” groups (non-parametric Mann Whitney test or “U-test”).
Median “worse cases” Median “good cases” p-value
N. pts N. pts
CD3 5 7 (6.5–12) 6 12.25 (9–35) 0.0267
CD8 5 7 (2–13) 6 9.25 (4–14) 0.119
CD20 5 1.5 (0–2.5) 6 1.5 (0–4.5) 0.925
https://doi.org/10.1371/journal.pone.0219566.t004
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CD37-/- mice have impaired antitumour responses [56]; however, the role of CD37 in the
tumour microenvironment is not clear and further investigations are needed. Tetraspanins in
the tumour microenvironment may have therapeutic potential via stimulation or inhibition of
immune cell functions, depending on the immune cell type [57].
There are numerous biomarkers that have proved to be clinically useful for other cancers
such as lung cancer [58], colorectal cancer [59], breast cancer [60] and melanoma [61], but
clinical application of biomarkers for PDAC has been somewhat limited. Indeed, the only
FDA-approved PDAC marker, the serum protein CA 19–9, was approved in the 1980s [62]. At
least 10% of patients do not express CA 19–9, however, and its level is easily affected by meta-
bolic abnormalities. Several studies have identified biomarkers that could be used as predictors
of clinical outcome for PDAC [63–66], but none of these involves the immune-related gene
signature revealed here.
The key findings from this study, that longer-surviving PDAC patients had higher levels of
intratumoural TILs and overexpressed five immune markers (TLR7, TNF, C1QA, FOXP3,
CD37), could have two main uses. Firstly, TIL levels and marker gene panel expression could
be used for clinical outcome prediction, stratification and treatment design for PDAC patients.
A previous study showed that a signature comprising another 15 genes was an independent
prognostic factor in two cohorts of PDAC patients. In contrast to our results, higher expres-
sion of these 15 genes was associated with poor OS [63]. Similarly, Sergeant et al identified
high co-expression of TGF-β1 and a panel of cell motility genes as independent predictors of
worse clinical outcome [64], while Van den Broek et al discovered that high expression of
ABCB1 and CXCR4 correlated with worse clinical outcome [65]. Furthermore, decreased levels
of DPEP1 and increased expression of TPX2 were independently associated with poor survival
[66]. Presumably, a wide panel of validated gene signatures would be most useful for outcome
prediction, stratification and therapeutic decision making.
Secondly, our findings could be useful in developing new PDAC treatments, for example in
combination with current immunotherapeutic strategies. Expression of the target genes identi-
fied here could be induced together with therapies modulating the tumour microenvironment
Fig 6. Levels of TIL markers in “worse cases” (Worse) and “good cases” (Good) of pancreatic adenocarcinoma.
The box plots represent the expression levels of CD3, CD8 and CD20 TIL subpopulations comparing the “worse case”
and “good case” groups. The lower table summarizes the statistical difference of TIL levels between the “worse case”
and “good case” groups (non-parametric Mann Whitney test or “U-test”).
https://doi.org/10.1371/journal.pone.0219566.g006
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to relieve immunosuppression, and/or approaches to break down the desmoplastic barrier sur-
rounding PDAC to facilitate target access for infiltrating T cells or therapeutic molecules [15].
Such strategies could be effected in combination with recently reported gene therapy and
oncologic vaccination approaches [67–69].
In summary, our data indicate that a gene signature comprising at least TLR7, TNF, C1QA,
FOXP3, and CD37 could be useful to improve the prediction of OS in PDAC patients.
Together with an assessment of TIL levels, such an immune system gene panel constitutes a
potential prognostic tool to permit a risk-based stratification of pancreatic tumour patients
into personalized treatment protocols towards improving the current abysmal clinical out-
come of these patients.
Future perspective
The findings in the paper might be useful in stratifying patients and indicating the best treat-
ment available for pancreatic cancer patients. In addition, our study could pave the way for
finding novel targets for the development of new drugs for this disease.
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